FindTrial
Sign In

Effect of the combination of hemodialysis and hemoperfusion on clearing interleukin-31

Effect of the combination of hemodialysis and hemoperfusion on clearing interleukin-31

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200063154
Enrollment
Unknown
Registered
2022-09-01
Start date
2022-09-12
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uremic pruritus

Interventions

Hemodialysis group:none
Hemodialysis combined with hemoperfusion group:none

Sponsors

LiQun Hospital of Putuo District, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients gave informed consent to the study content and had complete medical history; 2. Receiving maintenance hemodialysis treatment for more than 3 months; 3. Aged over 18 years.

Exclusion criteria

Exclusion criteria: 1. Patients with active malignant tumor, cholestatic liver disease or acute hepatitis; 2. Active infection; 3. There are consciousness disorders, mental diseases can not cooperate; 4. Patients with primary dermatosis; 5. Patients whose dialysis mode has changed in the past 3 months; 6. Refuse to participate.

Design outcomes

Primary

MeasureTime frame
IL-31;Visual Analogue Scale Score;—

Secondary

MeasureTime frame
Serum Calcium;Serum Phosphorus;Parathyroid Hormone;C-reactive Protein;ß2-microglobulin;—

Countries

China

Contacts

Public ContactZhang Xin

LiQun Hospital of Putuo District, Shanghai

15921510665@163.com+86 15921510665

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026